Gastroenterology
Volume 136, Issue 5 , Pages 1796-1805.e6, May 2009

A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C

  • Hironobu Tsukada

      Affiliations

    • Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Kasumi, Minami-ku, Hiroshima, Japan
    • Pharmacology Research Laboratories, Drug Research Division, Dainippon Sumitomo Pharma Co., Ltd, Kasugade Naka, Konohana-ku, Osaka, Japan
  • ,
  • Hidenori Ochi

      Affiliations

    • Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Kasumi, Minami-ku, Hiroshima, Japan
  • ,
  • Toshiro Maekawa

      Affiliations

    • Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Kasumi, Minami-ku, Hiroshima, Japan
  • ,
  • Hiromi Abe

      Affiliations

    • Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Minami-ku, Hiroshima, Japan
  • ,
  • Yoshifumi Fujimoto

      Affiliations

    • Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Minami-ku, Hiroshima, Japan
  • ,
  • Masataka Tsuge

      Affiliations

    • Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Minami-ku, Hiroshima, Japan
  • ,
  • Hiroshi Takahashi

      Affiliations

    • Laboratory for Statistical Analysis, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Shirokanedai, Minato-ku, Tokyo, Japan
  • ,
  • Hiromitsu Kumada

      Affiliations

    • Department of Hepatology, Toranomon Hospital, Toranomon, Minato-ku, Tokyo, Japan
  • ,
  • Naoyuki Kamatani

      Affiliations

    • Laboratory for Statistical Analysis, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Shirokanedai, Minato-ku, Tokyo, Japan
  • ,
  • Yusuke Nakamura

      Affiliations

    • Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan
  • ,
  • Kazuaki Chayama

      Affiliations

    • Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), Kasumi, Minami-ku, Hiroshima, Japan
    • Department of Medical and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Minami-ku, Hiroshima, Japan
    • Corresponding Author InformationReprint requests Address requests for reprints to: Kazuaki Chayama, MD, PhD, Laboratory for Digestive Diseases, Center for Genomic Medicine, RIKEN (The Institute of Physical and Chemical Research), 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. fax: (81) 82-255-6220

Received 3 January 2008; accepted 29 January 2009. published online 02 February 2009.

Background & Aims

This study aimed to identify host single nucleotide polymorphisms (SNPs) that are associated with the efficacy of interferon (IFN) therapy in patients with chronic hepatitis C.

Methods

We examined whether 116 tagging-SNPs from 13 genes that are involved in type I IFN signaling associate with the outcome of IFN therapy in Japanese case-control groups; the study included 468 sustained responders and 587 nonresponders.

Results

We identified 2 SNPs (rs3792323 [A/T] and rs616589 [G/A]), located in intron 2 of mitogen-activated protein kinase–activated protein kinase 3 (MAPKAPK3) that were associated with the outcome of IFN therapy in patients infected with hepatitis C virus (HCV) genotype 1b (P = 4.6 × 10−5 and 4.8 × 10−5, respectively). The 2 SNPs were in strong linkage disequilibrium and multivariate logistic regression analysis showed that rs3792323 is an independent factor associated with the IFN efficacy (genotype 1b; P = .0011). MAPKAPK3 is a kinase involved in the mitogen and stress responses, but the biological significance of MAPKAPK3 in IFN responses is poorly understood. By using an allele-specific transcript quantification assay in liver biopsy, we showed that allele-specific expression of MAPKAPK3 messenger RNA, corresponding to the risk allele for nonresponse, was significantly higher than that of the other allele. Luciferase reporter assay data indicated that overexpression of MAPKAPK3 inhibits IFN-alfa–induced gene transcription via IFN-stimulated response element and IFN-γ–activated site.

Conclusions

The SNP rs3792323 in MAPKAPK3 associates with the outcome of IFN therapy in patients with HCV genotype 1b. Our functional analyses indicate that MAPKAPK3 inhibits IFN-alfa–induced antiviral activity.

Abbreviations used in this paper: GAS, interferon-γ–activated site, IFN, interferon, IFNAR1, type I interferon receptor-1, ISRE, interferon-stimulated response element, JAK, Janus-activated kinase, MAP, mitogen-activated protein, MAPKAPK, mitogen-activated protein kinase–activated protein kinase, MAPKK, mitogen-activated protein kinase kinases, NR, nonresponders, SNPs, single nucleotide polymorphisms, SR, sustained responders, STAT, signal transducer and activator of transcription

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflicts of interest The authors disclose no conflicts.

 Funding This study was supported by a grant from the Japanese Millennium Project, and in part by Dainippon Sumitomo Pharma Co, Ltd. This work was also supported in part by a Grant-in-Aid for Scientific Research and Development from the Ministry of Education, Sports, Culture, and Technology and the Ministry of Health, Labor, and Welfare.

PII: S0016-5085(09)00165-6

doi:10.1053/j.gastro.2009.01.061

Gastroenterology
Volume 136, Issue 5 , Pages 1796-1805.e6, May 2009